Efficacy of topical corticosteroids in nickel-induced contact allergy

Hachem, Jean-Pierre; Paepe, Kristien De; Vanpee, Els; Bogaerts, M.; Kaufman, Leonard; Rogiers, Vera; Roseeuw, Diane

doi:10.1046/j.0307-6938.2001.00963.x

Cited by 32 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inflammatory skin diseases, including atopic dermatitis, psoriasis, and contact dermatitis are among the most common skin conditions affecting adults and children 1–3 . The mainstay of treatment for these diseases is topical steroids 4–6 . In the case of atopic dermatitis, topical immunosuppressant drugs have recently been introduced 7,8 .…”

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model

2004

View full text Add to dashboard Cite

The anti-inflammatory activity of topical nanocrystalline silver cream was assessed and compared with the effects of topical steroids and currently available immunosuppressants using a guinea pig model of allergic contact dermatitis. Dermatitis was induced with dinitrochlorobenzene and treated with different concentrations of nanocrystalline silver, medium and high potency steroids, tacrolimus and pimecrolimus, or appropriate vehicles once daily for 5 days. Erythema was evaluated daily (on a score of 0 to 4, from absent to very severe) and histopathology of the skin biopsies was evaluated after 5 days of treatment. Prior to treatment, the average scores of erythema in all the groups were in the range of 3(+) to 4(+). In the no treatment and vehicles groups these scores remained at about this level for the subsequent 5 days of the study. Nanocrystalline silver reduced erythema within 1 day of treatment in a concentration-dependent manner with significant reduction at silver concentrations of 0.5% and 1% (P < 0.05) and this reduction progressed throughout the study period. Steroids and immunosuppressants produced similar decreases in erythema, with no significant differences compared to 0.5% and 1% nanocrystalline silver. In skin biopsies scored for degree of inflammatory response, effects of treatments mirrored erythema results. This study suggests that nanocrystalline silver cream may have therapeutic potential for topical treatment of inflammatory skin diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model

2004

View full text Add to dashboard Cite

show abstract

“…Topical corticosteroids are nowadays the mainstay of therapy for allergic contact dermatitis, but the need for potent formulations carries an associated risk of atrophy, telangiectasia, other local adverse effects and systemic absorption. In addition, the development of tachyphylaxis or tolerance to their therapeutic effect and the potential for delay of epidermal regeneration, as suggested by late transepidermal water loss measurements (1), are significant drawbacks to the use of topical corticosteroids and justify the search for better therapeutic alternatives. Topical calcineurin inhibitors, which have recently been introduced to our therapeutic armamentarium, are promising in this respect.…”

mentioning

confidence: 99%

Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema

et al. 2003

View full text Add to dashboard Cite

The aim of this study was to evaluate the ability of topical tacrolimus 0.1% under occlusion for 48 h to suppress nickel-elicited allergic contact dermatitis in a randomized, petrolatum- and mometasone furoate 0.1% ointment-controlled double-blind, intra-individual study which included 28 women volunteers. 3 closed patch tests (Finn Chambers on Scanpor, Epitest Ltd Oy, Tuusula, Finland) containing 0.1 ml of 5% nickel sulfate in petrolatum were applied on day 0. After removal on day 2, the study compounds were applied under occlusion for 48 h. The eczema reaction and the degree of erythema were evaluated clinically and by reflectance spectrophotometry at days 4 and 7, respectively. Mean visual scores corresponding to petrolatum-treated sites were significantly higher than those corresponding to both mometasone furoate and tacrolimus at days 4 (P < 0.001) and 7 (P < 0.001). In both tacrolimus- and mometasone furoate-treated sites, there was a significant decrease in visual scores with time (P < 0.001) from day 2 to day 7, and the corresponding mean decreases in scores were 0.73 and 1.04, respectively. The difference between both was 0.30 in favour of tacrolimus (95% confidence intervals, -0.04 and 0.65), although this did not reach statistical significance (P = 0.084). Mean erythema index values were similar at day 2. Significant differences among treatment sites were seen at days 4 (P < 0.001) and 7 (P < 0.001). The decrease was significantly more pronounced on day 7 in patches where tacrolimus had been supplied (P < 0.5). This method might provide useful means to compare different concentrations and/or presentations of tacrolimus or other calcineurin inhibitors and topical anti-inflammatory agents.

show abstract

“…In addition, potential novel indications of FP corresponding to the beneficial effect on skin barrier disruption caused by nickelinduced allergic contact dermatitis come to horizon [66,67]. Studies about FP are accumulating, and results suggest an increased overall therapeutic potential in terms of efficacy and tolerability due to its increased affinity and improved GR pharmacokinetics.…”

Section: Resultsmentioning

confidence: 99%

Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases

Roeder

Schaller

Schäfer‐Korting

et al. 2004

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid.

show abstract

Efficacy of topical corticosteroids in nickel-induced contact allergy

Cited by 32 publications

References 16 publications

Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model

Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model

Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema

Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases

Contact Info

Product

Resources

About